本文得到第一三共支持，谨致谢意
东山浩
第一三共（中国）投资有限公司首席医学官
医学总部总经理
东山浩博士，第一三共（中国）投资有限公司首席医学官，医学总部总经理，ICOS（国际肿瘤心脏病学会）中国中心委员。他在国内外著名大学、医疗卫生研究机构和大型跨国公司有着近30年的临床医学、教育与研究、临床研发、国际医学事务开拓和管理经验，包括：日本国立健康营养研究所和国立東京医科齿科大学难治疾病研究所从事并负责尖端医学项目研究，设立并任职IQVIA中国和上海首席代表以及中国临床开发总部总负责人，设立并任职IQVIA日本PMP部部长，第一三共集团公司全球医学事务管理委员会董事委员，第一三共集团公司全球医学事务基础医疗治疗领域委员会董事委员，第一三共集团公司全球医学事务肿瘤治疗领域委员会董事委员，第一三共集团公司亚太区肿瘤医学事务总负责人，第一三共集团公司亚太区医学事务总负责人。东山浩博士毕业于原上海医科大学和日本国立東京医科齿科大学，获得后者的医学博士学位。
第一三共提出关注肿瘤共病的初衷是什么？
基于肿瘤共病医学平台，您认为哪些学术科研方向值得探讨？
您认为医学事务人才培养如何助力“肿瘤共病”这项医学策略的发展？
What motivated Daiichi Sankyo to initiate a novel medical strategy targeting tumor multimorbidities?
There has been a steady rise in the number of patients afflicted with both tumors and chronic diseases in China, leading to the emergence of new disease burdens and significant unmet medical needs.
At Daiichi Sankyo, our mission revolves around patient-centered philosophy, scientific leadership, and clinically oriented solutions to address these unmet medical needs, ultimately striving to improve quality of life worldwide. Recognizing the societal demands, our medical team in China is at the forefront of pioneering "tumor multimorbidities" as an innovative field of medical affairs.
We are dedicated to collaborating with health care provider opinion leaders, medical institutions and academic societies to advance research and development in diagnosing and treating tumor multimorbidities. Our goal is to provide scientifically grounded medical support for cancer patients, benefiting a wide spectrum of individuals and contributing to China's healthcare initiatives.
Daiichi Sankyo's product pipeline comprehensively covers various areas, including oncology and specialty diseases. With our esteemed professional talents, extensive knowledge, rich experience, and numerous external academic network, we are committed to improving the diagnosis and treatment of tumor multimorbidities, both within China and globally.
How will you turn the vision of a collaborative platform for tumor multicomorbidities you have outlined into reality?
Proposing and/or establishing a collaboration platform for tumor multimorbidities requires close cooperation among government entities, healthcare systems, and enterprises, forming a tripartite collaboration model of "government-academia-enterprise."
Firstly, under the guidance of national policies, pharmaceutical companies, hospitals, medical schools, and professional societies collaborate closely to ensure sustainable development in managing tumor multimorbidities.
Secondly, the active involvement and strong support of seniorleaders from medical schools and hospitals are essential for efficiently implementing management mechanisms and establishing collaboration platforms for tumor multimorbidities. Academicians, renowned experts, and researchers play pivotal roles in constructing and disseminating the theoretical framework, as well as conducting basic, translational, and clinical research to advance the diagnosis and treatment of tumor multimorbidities.
Lastly, Daiichi Sankyo China can scientificallysupport professional societies in developing and upgrading guidelines and expert consensus on the diagnosis and treatment of tumor multimorbidities. We can also assist hospitals and research institutions in conducting basic and clinical research. Furthermore, collaborating with healthcare institutions and academic groups, we aim to enhance patient education and public awareness, ultimately improving overall health literacy.
What research directions do you find promising for exploration through this collaborative platform?
The concept of tumor multimorbidities is relatively novel and still lacks comprehensive understanding within the medical community. Consequently, there exists a wide array of academic research avenues ripe for exploration within the framework of a collaborative medical platform for tumor multimorbidities.
Primarily, there exists a significant dearth of epidemiological and clinical evidence. Our understanding of tumor multimorbidities remains in its nascent stages, hindered by limited relevant data. This hampers our ability to grasp the complete clinical spectrum and characteristics of various tumor multimorbidities, impeding the establishment of a comprehensive management system. Seeking collaboration opportunities to discuss the significance and feasibility of such evidence is crucial, providing foundational data for developing a framework for tumor multimorbidities.
Furthermore, there is a pressing need for basic and translational research on tumor multimorbidities. The pathogenesis of comorbidities like stroke and heart disease in cancer patients remains unclear. Clarifying the efficacy and safety of conventional cardiovascular drugs, such as anticoagulants, antihypertensives, and antihyperlipidemic drugs, in managing tumor multimorbidities is paramount.
Given the novelty and complexity of the concept, managing tumor multimorbidities poses new challenges across the medical spectrum, impacting clinical diagnosis, treatment, caregiving, and drug management. Daiichi Sankyo China is committed to addressing these challenges collaboratively, supporting domestic healthcare professionals in conducting comprehensive research. Through continuous exploration and innovation, we aim to introduce effective solutions rooted in Chinese research to benefit patients globally.
第一三共（中国）投资有限公司（以下简称“本公司”）是由跨国制药企业——第一三共集团于2011年11月在上海设立的外商独资投资性公司，并于2012年12月被认定为跨国公司地区总部。
本公司作为第一三共集团在中国的地区总部，负责统一管理中国地区所有业务，以推进高效的决策和战略性的投资，实现第一三共集团在中国业务的进一步成长，共同致力于为中国医药事业服务。其中国地区子公司——第一三共制药（上海）有限公司作为生产基地，生产的药品被广泛用于各个医疗领域。
目前本公司在华有员工约一千四百余名，并在全国各级城市设有分支机构开展医药事业。我们的产品覆盖肿瘤、心血管、抗感染等各大治疗领域，其中肿瘤领域已成为第一三共的战略重点。目前，第一三共多款重磅 ADC产品已获批或正在申请多项适应症，其在乳腺癌、胃癌、肺癌等治疗领域价值斐然；未来也有计划在华布局更多的抗肿瘤药物，以期为更多肿瘤患者带来福祉。
我们始终对创新充满热情，成为“为社会可持续发展做出贡献的创新型全球医疗保健公司”是第一三共2030年的企业愿景，每一位第一三共员工将为此不懈努力。
联系方式
地址：上海市静安区南京西路1717号会德丰国际广场51楼
电话：86-21-60397200
网站：https://www.daiichisankyo.com.cn/
版权信息
本文由嘉会医学研究和教育集团（J-Med）与《新英格兰医学杂志》（NEJM）联手打造的《NEJM医学前沿》翻译、编写或约稿。中译全文及所含图表等由NEJM集团独家授权。如需转载，请留言或联系nejmqianyan@nejmqianyan.cn。未经授权的翻译是侵权行为，版权方保留追究法律责任的权利。
点击下方名片，关注《NEJM医学前沿》
